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INTRODUCTION:  Anaplastic  carcinoma  of  the  thyroid  is  a rare  but aggressive  malignancy  which  can  present
with a  rapidly  enlarging  neck  mass  or compressive  sequelae  of  cough,  dyspnoea,  dysphagia  and  hoarse-
ness. Treatment  of  such  tumours  is commonly  palliative  however  they  occasionally  represent  surgical
challenges  due  to their  rapid  growth,  diagnostic  difﬁculty  and  locoregional  spread.
PRESENTATION  OF  CASE:  A 75  year-old  retired  veterinary  surgeon  was  referred  with  a 2  month  history
of  a  painless,  enlarging  neck  mass.  The  patient  denied  any  secondary  compressive  symptoms  or  generaline needle aspiration cytology
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symptoms  of malignancy.  On  examination  a  large  right-sided  neck  mass  measuring  7  cm  × 5 cm was
appreciated  which  was  ﬁxed,  hard  and  irregular  with  associated  adenopathy.
DISCUSSION:  We  discuss  the diagnostic  challenges  posed  by anaplastic  carcinoma  of the  thyroid  and  the
difﬁculties  in selecting  the  appropriate  intervention  in  this  aggressive  disease  process.
CONCLUSION:  Anaplastic  carcinoma  of the  thyroid  is encountered  infrequently  in  clinical  practice  and
can generate  diagnostic  and  therapeutic  challenges.
sevie© 2013 Published by El
. Introduction
Anaplastic carcinoma of the thyroid is a rare but aggressive
alignancy of the head and neck region. In distinction from dif-
erentiated carcinoma of the thyroid, anaplastic is classiﬁed as
ndifferentiated carcinoma, heralding its aggressive nature. Clin-
cally the majority of patients will present with a rapidly enlarging
eck mass or compressive sequelae of cough, dyspnoea, dysphagia
nd hoarseness. Histologically the tumour is composed of undif-
erentiated cells which show immunohistochemical evidence of
pithelial differentiation. Expression of usual markers of thyroid
rigin, such as Thyroglobulin or Thyroid Transcription Factor-1
TTF-1) is exceptional and diagnosis can prove challenging. Poor
rognostic factors include male sex, age over 60, and distant
etatasis.1
. Case report
A 75 year-old retired veterinary surgeon was referred to a
ertiary referral centre with a 2 month history of a painless, enlarg-
ng neck mass. The patient denied local symptoms of dysphagia,
ysphonia or otalgia and did not report systemic symptoms of
eight loss or night sweats. He was an ex-smoker with a 75 pack
ear history. Clinical examination showed a right-sided neck mass
pproximately 7 cm × 5 cm in size which extended through both
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anterior and posterior triangles of the neck. On palpation the mass
was irregular and ﬁxed. Cervical lymphadenopathy was appreci-
ated and the patient was clinically euthyroid.
Routine haematological and biochemical investigations, Cal-
citonin, Carcinoembryonic antigen (CEA), thyroid function tests
(TFTs) and parathyroid hormone levels (PTH) were all within nor-
mal  limits. A needle core biopsy of the neck mass showed a poorly
differentiated spindle cell tumour with large pleomorphic nuclei
and abundant abnormal mitoses. A wide panel of immunohis-
tochemistry was carried out to further classify, and the tumour
cells were positive for cytokeratin (Fig. 1) (AE1/AE3 and CAM 5.2),
vimentin (Fig. 2) and CD 10. Other markers, including TTF-1, thy-
roglobulin, CK5/6 and p63 were negative. This immunoproﬁle was
consistent with metastatic poorly differentiated sarcomatoid car-
cinoma and the differential diagnosis included origin from the
kidney, lung or thyroid.
This result prompted both magnetic resonance imaging (MRI)
of the kidneys and a computed tomography (CT) scan of the thorax,
abdomen and pelvis, both of which were non contributory.
To further deﬁne the anatomy of the malignant neck mass
a CT neck (Fig. 3) was  performed. It showed a 6 cm mass
suggestive of a right oropharyngeal carcinoma with bulky right-
sided neck lymphadenopathy. The follow-up nasal endoscopy
was normal. Finally staging was concluded with a positron
emission tomography (PET) scan (Fig. 4), which was signif-
icant for the right neck lesion but also for a discrete area
Open access under CC BY-NC-ND license.in the right colon which was 18-ﬂuorodeoxyglucose (18-FDG)
avid. On a subsequent colonoscopy this ﬁnding on PET proved
to be a false positive, with no corresponding abnormality
found.
ess under CC BY-NC-ND license.
CASE  REPORT  –  OPEN  ACCESS
M.D. O’Sullivan et al. / International Journal of Surgery Case Reports 4 (2013) 378– 381 379
Fig. 1. Cells staining positive with cytokeratin.
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dFig. 2. Cells staining strongly positive with vimentin.
. Surgical dilemma
The case was discussed at the Head and Neck Multidisciplinary
eeting (MDM). Given the apparent absence of any further lesions
n radiological scans and based on the anatomy of the lesion, it was
ecided that the appropriate management was a right level V neck
issection with removal of the mass.
Fig. 3. Cross-sectional CT image of the right neck mass.Fig. 4. Coronal PET scan displaying 18-FDG avid neck mass and right colon.
Intraoperatively, following the removal of the neck mass, it was
noted that there was enlargement of the right lobe of the thyroid.
An intraoperative consultation was  requested from the endocrine
surgical team, and an on-table FNA was  performed for cytological
examination. Subsequently the patient had uncomplicated opera-
tive and post operative course.
The on-table FNA of the right thyroid lobe showed a malignant,
highly cellular specimen with numerous pleomorphic tumour cells,
including bizarre giant cells and mitotic ﬁgures.
The excised neck mass had a lobulated appearance and was
approximately 70 mm in maximum dimension (Fig. 5). Histologi-
cal examination showed a high grade tumour composed of spindle
cells and giant cells extensively replacing lymph nodes and soft
tissue in the neck. The morphology and immunophenotype was
similar to the previous core biopsy, with tumour cells positive for
cytokeratin and vimentin. TTF-1 and Thyroglobulin were negative.
In conjunction with the results of the FNA, this was  interpreted
as metastatic anaplastic carcinoma arising within adjacent thyroid
gland, in which loss of expression of typical immunohistochemical
markers of thyroid origin is usual.
The case was referred to the endocrine surgical team for further
management. At this point in time the case presented a surgical
dilemma, with both indications and contraindications for a total
thyroidectomy. Operative indications included a focus of malig-
nancy in the right lobe of the thyroid, however given the diagnosis
of anaplastic carcinoma and the local extent of the tumour it would
Fig. 5. Gross specimen of dissected lymph node containing anaplastic carcinoma.
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e classiﬁed as stage IVB (extrathyroidal spread without distant
etastases). Currently in the literature surgical intervention at this
tage is controversial.2,3
The case was discussed at the thyroid cancer MDM  and it was
ecided that the best management included a total thyroidectomy
nd adjuvant radiotherapy. This operation was undertaken one
onth after the initial Level V neck dissection. Intraoperatively the
ight lobe of the thyroid was grossly enlarged, extending posteri-
rly to the oesophagus and inferiorly to the subclavian vein. The
ight recurrent laryngeal nerve was involved in the tumour and
as formally divided. The left lobe of the thyroid was grossly nor-
al. The thyroid was excised without further complication. The left
arathyroids were visualised and preserved. The patient was  ini-
iated on oral calcium and levothyroxine postoperatively, had an
ncomplicated recovery from surgery, and was discharged in the
ollowing six days.
Histology of the excised thyroid gland showed a tumour, 73 mm
n size, composed of both anaplastic carcinoma and papillary carci-
oma with follicular variant. Hashimoto’s thyroiditis was  present
ithin the remaining thyroid parenchyma. There was  extension of
he tumour into the soft tissue and fat around the thyroid.
Despite surgery and a referral for adjuvant radiotherapy, the
atient died nineteen weeks post-operatively.
. Discussion
The differential diagnosis of a neck mass is extensive and varies
ith age. This case described a rare cause of a neck mass, with
naplastic carcinoma of the thyroid having an age-adjusted annual
ncidence of two per million persons.4 It is one of the most aggres-
ive neoplasms known to medicine. In this case, the site of the
rimary tumour proved elusive and immunohistochemistry could
nly generate a differential diagnosis for potential primary sites.
adiological investigations were ineffective, with the CT neck cha-
acterising the mass as potentially sarcomatous and oropharyngeal
n origin. Ultimately, it was during intraoperative inspection of the
urgical site after the dissection of the neck mass, that the primary
esion within the thyroid was discovered, and conﬁrmed cytologi-
ally.
Due to the extensive involvement of the cervical soft tissue, the
umour was staged retrospectively as IVB, extrathyroidal spread
ithout distant metastases.
. UICC stage IV: subdivision5
IVA Tumour limited to thyroid
IVB Tumour with extracapsular extension
IVC Tumour presence of distant metastasis
Currently there is debate in the literature as to at what
tage surgical intervention is indicated. A study by McIver et al.,
howed a cohort of patients suffering from anaplastic carci-
oma had no beneﬁt in survival following surgical resection
f the tumour.6 It must be noted, that in this study 46% of
he included cohort had evidence of metastatic disease at the
ime of diagnosis and were therefore stage IVC. In contrast, a
tudy by Haigh at al showed a survival advantage following
esection of localised tumour combined with postoperative adju-
ant chemoradiotherapy, even with persistent minimal disease
n vital structures.7 Recently it has been shown that subdividing
tage IVB could have both therapeutic and prognostic signiﬁcance,8uggesting that the degree of extracapsular extension is clinically
mportant.
The excised thyroid tumour was composed of both anaplastic
nd papillary carcinoma. This ﬁnding highlights the pathogenesisPEN  ACCESS
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of  anaplastic tumours. Through dedifferention, the cells of a papil-
lary carcinoma change to those of an anaplastic carcinoma, evident
histologically as epithelial–mesenchymal transition. Genetically
this conversion is driven by mutations of p53 tumour suppressor
gene, which is found at high frequency in anaplastic carcinoma.9
In vitro studies have exploited this fact, and have employed ade-
novirus as a vector for gene therapy, reintroducing p53 tumour
suppressor gene to anaplastic cells and subsequently improving
their chemosensitivity.10 Other possible novel therapies include
peroxisome proliferator-activated receptor gamma  (PPAR)  ago-
nists, which have been shown to induce apoptosis in anaplastic
cancer cell lines.11 Clinically a recent case report has shown a
patient with gross residual disease following resection of anaplas-
tic carcinoma has had 18 months of complete response with
the addition of sunitinib, a tyrosine kinase receptor inhibitor, to
chemoradiotherapy.12
In this case we would like to emphasise the diagnostic challenge
posed by anaplastic carcinoma of the thyroid and the difﬁculty in
selecting the appropriate intervention in this aggressive disease
process.
Conﬂict of interest statement
None.
Funding
None.
Ethical approval
Written informed consent was  obtained from the patient for
publication of this case report and accompanying images.
Author contributions
M.D. O’Sullivan and K.S. McAnena contributed toward writ-
ing of the manuscript; P.S. Waters contributed toward revision
of manuscript; C. Egan contributed toward the histopathological
aspects of the case. P.J. McCann and M.J. Kerin carried out a ﬁnal
review on the manuscript prior to submission.
References
1. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplas-
tic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer
2005;103(7):1330.
2.  Sherman SI. Thyroid carcinoma. Lancet 2003;361(9356):501–11.
3.  Wein RO, Weber RS. Anaplastic thyroid carcinoma: palliation or treatment?
Current Opinion in Otolaryngology and Head and Neck Surgery 2011;19(April
(2)):113–8.
4. Mazzaferri EL. Undifferentiated thyroid carcinoma and unusual thyroid malig-
nancies. In: Endocrine tumors. Boston: Blackwell Scientiﬁc Publications; 1993. p.
378.
5.  Ito Y, Higashiyama T, Hirokawa M,  Fukushima M,  Yabuta T, Tomoda C,
et  al. Investigation of the validity of UICC stage grouping of anaplastic
carcinoma of the thyroid. Asian Journal of Surgery 2009;32(January (1)):
47–50.
6.  McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, et al. Anaplas-
tic thyroid carcinoma: a 50-year experience at a single institution. Surgery
2001;130(December (6)):1028–34.
7. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD,  Quivey JM,  et al.
Completely resected anaplastic thyroid carcinoma combined with adjuvant
chemotherapy and irradiation is associated with prolonged survival. Cancer
2001;91(12):2335–42.
8.  Ito KI, Hanamura T, Murayama K, Okada T, Watanabe T, Harada M,  et al. Mul-
timodality therapeutic outcomes in anaplastic thyroid carcinoma: improved
survival in subgroups of patients with localized primary tumors. Head and Neck
2011, http://dx.doi.org/10.1002/hed.21721.
9. DeLellis RA. Pathology and genetics of thyroid carcinoma. Journal of Surgical
Oncology 2006;94(8):662–9.
 –  O
rnal of
1
1CASE  REPORT
M.D. O’Sullivan et al. / International Jou
0.  Blagosklonny MV,  Giannakakou P, Wojtowicz M,  Romanova LY, Ain KB, Bates SE,
et  al. Effects of p53-expressing adenovirus on the chemosensitivity and differ-
entiation of anaplastic thyroid cancer cells. Journal of Clinical Endocrinology and
Metabolism 1998;83(July (7)):2516–22.
1. Miccoli P, Materazzi G, Antonelli A, Panicucci E, Frustaci G, Berti P,
et  al. New trends in the treatment of undifferentiated carcinomas of
1PEN  ACCESS
 Surgery Case Reports 4 (2013) 378– 381 381
the thyroid. Langenbeck’s Archives of Surgery 2007;392(July (4)):397–
404.
2.  Schoenfeld JD, Odejide OO, Wirth LJ, Chan AW.  Survival of a patient
with anaplastic thyroid cancer following intensity-modulated radiothe-
rapy and sunitinib—a case report. Anticancer Research 2012;32(May (5)):
1743–6.
